Aclaris Therapeutics ACRS
$3.44 −$0.06 (-1.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.44 0.00%
Open$3.44
Prev close$3.50
Day range$3.40 – $3.55
Volume2.19M
Market cap$545.63M
P/E (TTM)–
Dividend yield–
ACRS Stock News
Headlines matching Aclaris Therapeutics or the ACRS ticker, most recent first.
- CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
- Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
- LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13
- Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12
- Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 Positive
- Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12
- Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10 Positive
- Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
- H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
- CCORF Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13
- Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11
- CCORF Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $13 Positive
No comments yet — be the first to weigh in on ACRS.
Sign in to join the discussion.